Seminars in Hematology
Volume 44, Issue 4 , Pages 252-258 , October 2007

Autologous Stem Cell Transplantation in Chronic Myeloid Leukemia

  • Eduardo Olavarria

      Affiliations

    • Corresponding Author InformationAddress correspondence to Eduardo Olavarria, MD, PhD, Catherine Lewis Centre, Haematology Department, Hammersmith Hospital., Du Cane Road, London W12 0NN, UK.

References 

  1. Buckner CD, Stewart P, Clift RA, et al. Treatment of blastic transformation of chronic granulocytic leukaemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol. 1978;6:96–109
  2. Goldman JM, Th’ng KH, Park DS, et al. Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukemia in blast-cell transformation. Br J Haematol. 1978;40:185–195
  3. Goldman JM, Catovsky D, Hows J, Spiers ASD, Galton DAG. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. Br Med J. 1979;1:1310–1313
  4. Haines ME, Goldman JM, Worsley . Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: Probable prolongation of survival in some patients. Br J Haematol. 1984;58:711–721
  5. Butturini A, Keating A, Goldman J, Gale RP. Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet. 1990;335:1255–1258
  6. Reiffers J, Trouette R, Marit G, et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol. 1991;77:339–345
  7. Reiffers J, Mahon FX, Boiron JM, et al. Autografting in chronic myeloid leukaemia: an overview. Leukemia. 1996;10:385–388
  8. Pigneux A, Faberes C, Boiron JM, et al. Autologous stem cell transplantation in chronic myeloid leukemia: A single center experience. Bone Marrow Transplant. 1999;24:265–270
  9. Hehlmann R, Hochhaus A, Berger U, Reiter A. Current trends in the management of chronic myelogenous leukemia. Ann Hematol. 2000;79:345–354
  10. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068–3076
  11. Daley GQ. Rationalizing autotransplant strategies for chronic myeloid leukemia. Leuk Lymphoma. 1996;21:353–358
  12. Bhatia R, Forman SJ. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;12:151–172
  13. Miller JS. Innovative therapy for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;12:173–206
  14. Carella AM, Frassoni F. ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia [Ph]-negative PBPC in chronic myelogenous leukaemia. Br J Haematol. 1996;95:213–214
  15. Carella AM, Lerma E, Corsetti MT, et al. Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood. 1999;83:1534–1539
  16. Bouzgarrou R, Reiffers J: Cellules souches circulantes et LMC: Mmodalités de prélèvement, congélation, décongélation, reconstitution hématologique après greffe. Presented at the Réunion du groupe Hémobiologie du FAG, Paris, France, October 22, 1991
  17. Reiffers J. Autologous transplantation in chronic myelogenous leukemia. Blood Transfusion Immunohematol. 1985;28:509–520
  18. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome positive chronic myelogenous leukemia. N Engl J Med. 1983;308:1493–1498
  19. Jazwieck B, Mahon FX, Pigneux A, et al. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of chronic myelogenous leukemia patients contains BCR-ABL negative progenitor cells. Exp Hematol. 1995;23:1509–1514
  20. Kirk JA, Reems JA, Roecklein BA, et al. Benign marrow progenitors are enriched in CD34+/HLA-DRlo population but not in the CD34+/38lo population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization. Blood. 1995;86:737–743
  21. Petzer AL, Eaves CJ, Lansdorp PM, et al. Characterization of primitive subpopulation of normal and leukemic cells in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood. 1996;88:2162–2171
  22. Brito-Babapulle F, Bowcock SJ, Marcus RE, et al. Autografting for patients with chronic myeloid leukaemia in chronic phase: Peripheral blood stem cells may have a finite capacity for maintaining haematopoiesis. Br J Haematol. 1989;73:76–81
  23. Reiffers J, Goldman JM, Meloni G, Cahn JY, Apperley J. Autologous stem cell transplantation (Auto-SCT) for chronic myeloid leukemia (CML) in chronic phase: A report of the European Blood and Marrow Transplant (EBMT) Group. 22nd Annual Meeting of the EBMT, Vienna (Austria) Bone Marrow Transplant. 1996;17:S3;(suppl 1, abstr 56)
  24. Reiffers J, Taylor K, Gluckman E, et al. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol. 1998;102:639–646
  25. Archimbaud E, Michallet M, Philip I, et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol. 1997;99:678–684
  26. Olavarria E, Parker S, Craddock C, et al. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: Effect of granulocyte-colony-stimulating factor mobilization. Haematologica. 2000;85:647–652
  27. Russo D, Martinelli G, Montefusco V, et al. Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy. Haematologica. 1999;84:953–955
  28. Meloni G, Russo D, Baccarani M, et al. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia (The Italian Co-operative Study Group on Chronic Myeloid Leukemia). Haematologica. 1999;84:707–715
  29. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Karyotype conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymphoma. 1993;11(suppl 1):277–280
  30. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A. Chronic Leukaemia Working Party of the EBMT (Autologous stem cell transplantation in chronic myelogenous leukaemia: A retrospective analysis of the European Group for Bone Marrow Transplant). Bone Marrow Transplant. 1994;14:407–410
  31. Goldman JM. Treatment of chronic myeloid leukaemia: Some topical questions. Baillieres Clin Haematol. 1997;10:405–421
  32. Olavarria E, Reiffers J, Boque C, et al. The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol. 2002;118:762–770
  33. Spencer A, Granter N, Fagan K, et al. Collection and analysis of peripheral blood mononuclear cells during haemopoietic recovery following PBSCT for CML: Autografting as an in vivo purging manoeuvre?. Bone Marrow Transplant. 1998;21:101–103
  34. Meloni G, De Fabritiis P, Alimena F. Autologous bone marrow transplantation or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. Bone Marrow Transplant. 1990;4(suppl 4):92–94
  35. Khouri IF, Kantarjian H, Talpaz M, et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukaemia: The MD Anderson experience. Bone Marrow Transplant. 1996;17:775–779
  36. McGlave PB, De Fabritiis P, Deisseroth J, et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet. 1994;343:1486–1488
  37. Simonsson B, Oberg G, Bjoreman M, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up. Acta Haematol. 2005;113:155–162
  38. Apperley JF, Boque C, Carella A, et al. Autografting in chronic myeloid leukaemia: A meta-analysis of six randomised trials. Bone Marrow Transplant. 2004;33:S28
  39. Olavarria E, Kanfer E, Szydlo R, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: A single-centre experience. Br J Haematol. 2000;108:769–777
  40. Boiron JM, Cahn JY, Meloni G, et al. Chronic myeloid leukaemia in first chronic phase not responding to α-interferon: Outcome and prognostic factors after autologous transplantation. Bone Marrow Transplant. 1999;24:259–264
  41. Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med. 1995;122:254–261
  42. Mahon FX, Faberes C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant alpha interferon. Blood. 1998;92:4059–4065
  43. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  44. Reiffers J, Cahn JY, Montastruc M, et al. Peripheral blood stem cell transplantation followed by recombinant alpha interferon for chronic myelogenous leukemia in chronic phase: preliminary results. Stem Cells. 1993;11:23–24
  45. Carlo-Stella C, Regazzi E, Andrizzi C, et al. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Haematologica. 1997;82:291–296
  46. Gladstone DE, Bedi A, Miller CB, et al. Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biol Blood Marrow Transplant. 1999;5:394–399
  47. Rowe JM, Rapoport AP, Ryan DH, et al. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant. 1999;24:1057–1063
  48. Rainey MG, Harrison P, Hows JM, et al. Spontaneous graft-versus-host disease following autologous peripheral blood progenitor cell transplantation in chronic myeloid leukaemia. Bone Marrow Transplant. 1996;17:1077–1079
  49. Drummond MW, Marin D, Clark RE, et al. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol. 2003;123:479–483
  50. Kreuzer KA, Kluhs C, Baskaynak G, et al. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: Safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol. 2004;124:195–199
  51. Perseghin P, Gambacorti-Passerini C, Tornaghi L, et al. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion. 2005;45:1214–1220
  52. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol. 1994;86:76–81
  53. Enright H, McGlave P. Bone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol. 1998;10:100–107

PII: S0037-1963(07)00120-5

doi: 10.1053/j.seminhematol.2007.08.003

Seminars in Hematology
Volume 44, Issue 4 , Pages 252-258 , October 2007

Article Tools

* Image Usage & Resolution